{"analyses":[{"ciLowerLimit":"-0.38","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.24","groupDescription":"Appetite: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.1912","paramType":"Difference in LS Mean","paramValue":"0.43","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.39","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.30","groupDescription":"Appetite: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.1866","paramType":"Difference in LS Mean","paramValue":"0.46","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"0.09","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.75","groupDescription":"Appetite: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0349","paramType":"Difference in LS Mean","paramValue":"0.92","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.20","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.14","groupDescription":"Nausea: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.8754","paramType":"Difference in LS Mean","paramValue":"0.47","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.31","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.08","groupDescription":"Nausea: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.8205","paramType":"Difference in LS Mean","paramValue":"0.38","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.86","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.51","groupDescription":"Nausea: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.3375","paramType":"Difference in LS Mean","paramValue":"-0.17","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.14","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.45","groupDescription":"Physical Fatigue: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.9138","paramType":"Difference in LS Mean","paramValue":"0.66","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.18","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.46","groupDescription":"Physical Fatigue: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.9011","paramType":"Difference in LS Mean","paramValue":"0.64","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.61","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.02","groupDescription":"Physical Fatigue: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.6618","paramType":"Difference in LS Mean","paramValue":"0.21","statisticalMethod":"MMRM analysis; 1-sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.83","upperLimit":"0.37","value":"-0.23"},{"groupId":"OG001","lowerLimit":"-0.36","upperLimit":"0.76","value":"0.20"},{"groupId":"OG002","lowerLimit":"-0.37","upperLimit":"0.82","value":"0.23"},{"groupId":"OG003","lowerLimit":"0.11","upperLimit":"1.27","value":"0.69"}]}],"title":"Appetite"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.82","upperLimit":"0.17","value":"-0.33"},{"groupId":"OG001","lowerLimit":"-0.32","upperLimit":"0.61","value":"0.14"},{"groupId":"OG002","lowerLimit":"-0.43","upperLimit":"0.55","value":"0.06"},{"groupId":"OG003","lowerLimit":"-0.98","upperLimit":"-0.02","value":"-0.50"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.85","upperLimit":"0.32","value":"-0.27"},{"groupId":"OG001","lowerLimit":"-0.16","upperLimit":"0.94","value":"0.39"},{"groupId":"OG002","lowerLimit":"-0.21","upperLimit":"0.96","value":"0.38"},{"groupId":"OG003","lowerLimit":"-0.63","upperLimit":"0.51","value":"-0.06"}]}],"title":"Physical Fatigue"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"description":"The CRCSD is a daily, self-reported questionnaire that measured severity of symptoms related to cancer cachexia: appetite, nausea, vomiting, and fatigue. Participants rated appetite, nausea and physical fatigue symptom every day, and weekly averages were calculated over the 7 days prior, from 0 to 10, where 0 = no symptom and 10 = worst possible symptom. Higher scores indicated more severe disease. CRCSD was analyzed using an MMRM model.","dispersionType":"90% Confidence Interval","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Part A: Change From Baseline in Cancer-Related Cachexia Symptom Diary (CRCSD) Scores at Week 12: Appetite, Nausea and Physical Fatigue","type":"SECONDARY","unitOfMeasure":"Units on a scale"}